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Summary
Gliomas are intrinsic brain tumours, which are classified
by the World Health Organization (WHO) into different
grades of malignancy, with glioblastoma being the most
frequent and most malignant subtype (WHO grade IV).
Mutations in the isocitrate dehydrogenase (IDH) 1 or 2
genes are frequent in lower (WHO II/III) grade tumours
but typically absent in classical glioblastoma. IDH muta-
tions are associated with a better prognosis compared
with IDH wild-type tumours of the same WHO grade. Fol-
lowing detection of a tumour mass by imaging, maximum
safe surgery as feasible is commonly performed to reduce
mass effect and to obtain tissue allowing histopathological
diagnosis and molecular assessment. Radiotherapy has
been the mainstay in the treatment of diffuse gliomas for
several decades. It provides improved local control, but is
not curative. Furthermore, several randomised trials have
shown that the addition of alkylating chemotherapy, ei-
ther temozolomide or nitrosourea-based regimens, to ra-
diotherapy results in prolonged survival. Tumour-treating
fields (TTFields) have emerged as an additional treat-
ment option in combination with maintenance temozolo-
mide treatment for patients with newly diagnosed glioblas-
toma. Treatment at recurrence is less standardised and
depends on the patient’s performance status, symptom
burden and prior treatments. Bevacizumab prolongs pro-
gression-free survival in newly diagnosed and recurrent
glioblastoma, but does not impact overall survival. How-
ever, in Switzerland and some other countries, it is still
considered a valuable treatment option to reduce clinical
symptom burden. Given the generally poor outcome for
these patients, various novel treatment approaches are
currently being explored within clinical trials including im-
munotherapeutic strategies such as immune checkpoint
inhibition and the brain-penetrant proteasome inhibitor
marizomib.
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Introduction
The present manuscript results from two ad hoc meetings
of Swiss neuro-oncologists that aimed to define current
standards of clinical practice as well as challenges in the
diagnosis and management of gliomas in adulthood, in-
cluding specific considerations for Switzerland. The neu-
ro-oncologists involved considered the European Associ-
ation of Neuro-Oncology (EANO) recommendations [1]
and, at single centres, NCCN guidelines valid for Switzer-
land, but there are country-specific challenges discussed
herein, as well as several recent developments not covered
in the currently available versions of these guidelines. This
consensus paper addresses the clinical and scientific evi-
dence, but does not seek to value interventions by relating
efficacy and cost.
Classification of gliomas
Gliomas are intrinsic brain tumours that most likely de-
velop from neuroglial progenitor cells. Traditionally, the
diagnosis of gliomas was based on histopathological fea-
tures alone according to the World Health Organization
(WHO) classification of primary brain tumours. The most
recent version of the WHO classification includes molec-
ular markers, which allows for a more accurate diagnosis
and prognosis. The vast majority of grade II gliomas and
approximately 60–70% of all anaplastic gliomas (WHO
grade III) harbour a mutation in the isocitrate dehydro-
genase (IDH) 1 or 2 genes, whereas only a minority of
glioblastomas, the most frequent and most malignant type
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of glioma, are IDH mutant [2]. A co-deletion of chromo-
some arms 1p/19q, also referred to as loss of heterozy-
gosity (LOH) 1p/19q, assigns the diagnosis of an oligo-
dendroglial tumour [3]. Recently, mutations in the histone
H3 gene (H3K27M) have been identified as a subgroup of
midline gliomas. These tumours show an extremely poor
prognosis and must be considered as high grade gliomas
[4]. It can be assumed that additional molecular markers,
such as the presence of telomerase reverse transcriptase
(TERT) promoter mutations or homozygous deletion of
CDKN2a, will allow for even more refined diagnoses and
become part of an updated version of the WHO classifica-
tion [5, 6]. In glioblastoma, and probably also other IDH
wild-type gliomas, methylation of the promoter region of
the O6-methylguanine DNA methyltransferase (MGMT)
gene is a predictive marker for benefit from alkylating
agents. Recently, genome-wide DNA methylation profil-
ing has been described as a valuable tool to classify prima-
ry brain tumours and may be integrated into routine diag-
nostics in the coming years [7].
Diagnosis and work-up
Gliomas may present with various neurological symptoms
or signs, including seizures, focal deficits, cognitive alter-
ations or any other focal neurological symptom or sign that
triggers an imaging procedure. Magnetic resonance imag-
ing (MRI) is the gold standard for the detection and mon-
itoring of gliomas and evaluation should be according to
RANO criteria [8]. Only patients who are unable to un-
dergo MRI should be examined by computed tomography
(CT). Amino acid positron emission tomography (PET)
has become increasingly available and may be used in se-
lected patients for various purposes including the delin-
eation of tumour extension, the definition of appropriate
biopsy spots in non-contrast-enhancing tumours and radio-
therapy planning, as well as monitoring of tumour growth
and response assessment (fig. 1) [9].
Once tumour tissue is available, a standard histopatholog-
ical examination will be performed (fig. 2), which sub-
sequently should be supplemented by molecular assess-
ments. These include the determination of the IDH status,
first by immunohistochemistry, which will reveal IDH
R132H-mutant tumours, representing approximately 90%
of all IDH-mutant gliomas. In patients younger than 60
years with negative immunohistochemistry, additional se-
quencing of the IDH genes is recommened to exclude less
frequent IDH 1 as well as IDH 2 mutations. IDH-mutant
tumours should be further assessed for the presence of a
1p/19q co-deletion [10]. Some sites prefer to determine the
1p/19q status only in tumours which are α-thalassaemia/
mental-retardation-syndrome-X-linked gene (ATRX) wild-
type by immunohistochemistry [11]. The determination of
the MGMT promoter methylation status may guide clinical
decision making, particularly in elderly glioblastoma pa-
tients (see below), but does not aid in diagnosis. TERT pro-
moter mutations may help to increase the diagnostic accu-
racy because they are common in oligodendrogliomas and
glioblastomas, but rare in lower grade astrocytomas. The
search for potentially “actionable” molecular alterations,
such mutations in the BRAF gene or NTRK gene fusions
may be considered, particularly in younger patients [12].
Larger next generation sequencing (NGS) panels are used
at different centres to identify such molecular alterations,
which are rare overall.
Following the diagnosis of a glioma, regular assessment of
the Karnofsky performance status (KPS) and a clinical ex-
amination are required to monitor the occurrence or devel-
opment of symptoms that may be related to the tumour or
therapy. The Neurologic Assessment in Neuro-Oncology
(NANO) scale provides a tool for a standardised clinical
evaluation of glioma patients [13]. Glioblastoma patients
are typically followed-up every 2–3 months, but longer in-
tervals may be warranted in patients with lower grade tu-
mours and those with prolonged stable disease.
Treatment
Surgery
Maximum safe surgical resection has been considered a
standard of care despite lack of evidence from randomised
clinical trials. In glioblastoma, 5-aminolevulinic acid-guid-
ed resection resulted in a higher rate of gross total re-
sections and in prolonged progression-free survival (PFS)
[14], but there was no effect on overall survival (OS) and
this trial was conducted prior to the introduction of temo-
zolomide. Similarly, the use of intraoperative MRI guid-
ance increased the percentage of patients with gross total
resection [15], but survival data were not reported. Thus,
Figure 2: Exemples of the histopathological features of
gliomas. Haematoxylin and eosin staining of tumour tissue speci-
mens. A. Anaplastic oligodendrogioma with typical cytoplasmatic
halos (“fried eggs”) which are the result of a fixation artifact (mag-
nification 400×). B. Glioblastoma with pseudopalisading necrosis
(magnification 200×). Images courtesy of G. Reifenberger, MD, In-
stitute of Neuropathology, Düsseldorf.
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any impact of extent of resection and residual tumour on
survival remains a matter of debate. The extent of resection
should be determined by MRI within 24–72 hours after the
intervention.
Radiotherapy
Radiotherapy has been used as a treatment for gliomas for
several decades. It is typically administered in 1.8–2 Gy
fractions up to a dose of 54–60 Gy. Prolongation of OS by
radiotherapy was demonstrated in high-grade gliomas 40
years ago [16]. In contrast, radiotherapy prolonged PFS but
not OS in patients with WHO grade II gliomas [17]. Partic-
ularly in elderly and frail patients affected by glioblastoma,
hypofractionated radiotherapy with a dose of 40 Gy given
in 15 fractions of 2.67 Gy has been established as a stan-
dard of care [18]. In glioblastoma patients, several studies
failed to demonstrate an impact on survival by dose esca-
lation or high precision techniques including brachyther-
apy, stereotactic boosts or hypofractionated schemes [19,
20]. However, techniques such as intensity-modulated ra-
diotherapy (IMRT) or volumetric modulated arc therapy
(VMAT) may improve safety via reduction of the dose to
healthy tissue. Dose escalation also did not prolong OS
in patients with low grade gliomas in two randomised tri-
als [21, 22]. While the number of studies demonstrating
superiority of combined radiochemotherapy compared to
radiotherapy alone across various WHO grades has con-
tinuously increased (see below), it has remained unclear
Figure 1: Representative imaging findings in glioma patients. A. Glioblastoma. T1-weighted contrast-enhanced MRI (left) and T2-weight-
ed MRI sequence (right). B. Oligodendroglioma WHO grade 2. T2/FLAIR-weighted MRI (left) and 18F-fluoroethyl-tyrosine (FET)-PET (right).
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whether irradiation may be safely deferred in subgroups of
patients, particularly with WHO grade II and III tumours.
This strategy has been partially integrated into standards
of care in elderly patients with MGMT promoter-methy-
lated glioblastoma who are not considered candidates for
combined radiochemotherapy. These patients benefit from
treatment with temozolomide alone and may receive radio-
therapy as salvage therapy [23, 24].
Systemic treatment
Data from several randomised trials have defined the role
of systemic therapy in the treatment of diffuse gliomas [1].
A randomised trial enrolling patients with a diagnosis of a
WHO grade II glioma considered to be at increased risk of
further progression (age of 40 years or more, or residual
tumour following resection) demonstrated that the addition
of procarbazine, lomustine and vincristine (PCV) to radio-
therapy prolongs PFS and OS compared with radiotherapy
alone [25]. In the European Organisation for Research and
Treatment of Cancer (EORTC) trial 22033-26033, temo-
zolomide alone yielded similar results to radiotherapy
alone [26]. Altogether, these data suggest that combined
modality treatment is uniformly superior to either radio-
therapy alone or alkylating agent chemotherapy alone.
Several studies have also demonstrated a survival benefit
upon addition of alkylating chemotherapy to radiotherapy
in patients with anaplastic gliomas (fig. 3). Long-term
analyses of two randomised trials showed that the com-
bination of radiotherapy and PCV was superior to radio-
therapy alone in patients with 1p/19q co-deleted anaplastic
gliomas [27, 28]. In patients with 1p/19q intact anaplastic
gliomas, radiotherapy followed by up to 12 cycles of main-
tenance treatment with temozolomide prolonged PFS and
OS compared with radiotherapy alone [29]. Whether the
addition of concomitant treatment with temozolomide to
radiotherapy provides an additional benefit in subgroups of
patients requires further analyses and longer follow-up of
the EORTC 26053 trial (CATNON).
Temozolomide became part of the standard treatment for
glioblastoma patients in 2005. Concomitant treatment dur-
ing radiotherapy followed by maintenance treatment with
temozolomide resulted in prolonged PFS and OS com-
pared with radiotherapy alone, a finding that was also re-
cently confirmed in elderly glioblastoma patients [30, 31].
Benefit from temozolomide is largely restricted to patients
with glioblastoma with methylation of the MGMT promot-
er [32]. However, in the absence of convincing alterna-
tives, such as within a clinical trial, and given the overall
good tolerability, most neuro-oncological centres treat all
glioblastoma patients with combined temozolomide-based
radiochemotherapy up to approximately 70 years of age as
long as the performance status is favourable (fig. 4). Based
on the CeTeG trial, in younger patients with good perfor-
mance status and MGMT promoter-methylated tumours,
the addition of the combination of lomustine and temo-
zolomide chemotherapy to and after radiotherapy may be
considered [33].
The addition of the vascular endothelial growth factor
(VEGF)-targeting agent bevacizumab to the standard of
Figure 3: Therapeutic options for patients with WHO grade II and III diffuse gliomas. Alternative treatment options which may considered
on an invididual base are indicated in brackets. The dotted arrow indicates that for IDH wild-type tumours without molecular features of
glioblastoma, the same therapeutic approach as for IDH mutant tumours should be considered.IDH = isocitrate dehydrogenase; WHO = World
Health Organization; RT = radiotherapy; TMZ = temozolomide; PCV = procarbazine; CCNU = vincristine.
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care in patients with newly diagnosed glioblastoma result-
ed in prolonged PFS but not OS [34–36] and was therefore
not approved in this situation.
Tumour-treating fields
Tumour-treating fields (TTFields) have emerged as a new
treatment modality for glioblastoma patients. TTFields are
low-intensity, intermediate-frequency (200 kHz) alternat-
ing electrical fields, which are applied to the tumour region
using specific transducer arrays. Administration of
TTFields in patients with recurrent glioblastoma, most of
them with multiple prior lines of therapy, did not result in
superior outcome compared with the control arm, where
the best available chemotherapy according to the treating
physician’s choice was allowed [37]. In contrast, the addi-
tion of TTFields to maintenance temozolomide in patients
with newly diagnosed glioblastoma prolonged PFS and OS
compared with standard treatment alone [38]. Treatment
with TTFields is usually well tolerated except for skin re-
actions [39]. Subgroups of patients with preferential bene-
fit from TTFields have not been identified. Controversies
regarding this treatment within the neuro-oncology com-
munity concern the unclear mode of action in vivo and the
discrepancy between efficacy in the front-line setting ver-
sus the recurrent setting.
Treatment at recurrence
For patients with recurrent glioma, treatment is less stan-
dardised. The benefit of re-resection at recurrence remains
contested because of the lack of evidence from prospective
trials. It is most likely limited to patients with focal tumour
recurrence who are candidates for a gross total resection.
Re-irradiation may be administered in selected patients
with small tumours, but its efficacy has not been assessed
in a randomised trial. Furthermore, several systemic thera-
py options are available and in use [40]. Patients who ini-
tially only received radiotherapy or alkylating chemothera-
py should be treated with the therapeutic modality not used
so far. Although patients with lower-grade tumours typi-
cally present with a good performance status at recurrence,
the situation may be different in glioblastoma where only a
fraction of patients qualify for further treatment [41]. Sys-
temic treatment options at recurrence comprise alkylating
agents including primarily nitrosoureas such as lomustine,
particularly in patients with MGMT-methylated tumours
[42, 43]. However, access to lomustine has become more
difficult as it is not licenced in Switzerland, in contrast to
carmustine, an analogue nitrosourea formulation that is ad-
ministered intravenously and less well studied in the con-
text of glioblastoma. Re-exposure to temozolomide is less
frequently used today than some years ago [44]. A posi-
tive trial compared temozolomide with procarbazine [45],
but this trial predated the introduction of temozolomide in-
to the first-line setting. Treatment options for patients with
MGMT-unmethylated tumours thus remain limited.
Bevacizumab was approved in Switzerland for patients
with recurrent glioblastoma in 2009. Similarly to the sit-
uation in the newly diagnosed setting, the addition of be-
vacizumab to lomustine in patients with recurrent glioblas-
toma prolonged PFS but not OS [43]. In line with these
data, a Swiss population-based analysis did not reveal pro-
longed survival of glioblastoma patients after the introduc-
tion of bevacizumab [41]. However, the drug remains a
useful option in patients with symptomatic tumours who
experience a clinical benefit due to relief of the mass ef-
fect.
Supportive therapy
Glioma patients frequently suffer from clinical symptoms
related to therapeutic interventions or directly to the tu-
mour, such as surrounding oedema. Steroids such as dex-
amethasone or prednisone have been used for decades to
reduce peritumoural oedema and thereby alleviate neuro-
logical symptoms. They should always be used at the low-
est effective dose and tapering should be considered as
soon as clinically justified [46]. Many glioma patients are
Figure 4: First-line therapy in patients with newly diagnosed glioblastoma. Patients older than 70 years with MGMT-methylated glioblas-
toma may receive combined temozolomide-based radiochemotherapy or monotherapy with temozolomide, depending on the performance sta-
tus as considered appropriate by the treating physician.IDH = isocitrate dehydrogenase; RT = radiotherapy; TMZ = temozolomide; MGMT =
O6-methylguanine-DNA methyltransferase.
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affected by seizures requiring treatment with anti-epilep-
tic drugs. Drug interactions,such as with chemotherapeutic
agents, should be considered. There is no indication for
primary prophylactic antiseizure medication in patients
with gliomas who never had a seizure [47]. Furthermore,
glioma patients must be monitored for the occurrence of
venous thromboembolic events, which should be adequate-
ly treated according to local guidelines as in other patients
unless there are clear-cut contraindications. Supportive
measures are the major therapeutic focus in patients who
present in poor performance status, unable to undergo ra-
diotherapy or chemotherapy [48].
Further developments and outlook
The role of re-resection in patients with recurrent glioblas-
toma shall be clarified in the ongoing ReSurge trial
(NCT02394626). Furthermore, immunotherapy has been
considered an attractive treatment option for glioma pa-
tients. However, so far, no immunotherapeutic agent has
been shown to prolong the survival of glioma patients.
This includes the EGFRvIII-targeting peptide vaccine
rindopepimut, which was explored in patients with newly
diagnosed glioblastoma and the PD-1 inhibitor nivolumab,
which was assessed in patients with recurrent glioblastoma
[49, 50]. Furthermore, the combination of nivolumab and
radiotherapy was not superior to temozolomide-based ra-
diotherapy in patients with newly diagnosed MGMT-un-
methylated glioblastoma (CheckMate 498
[NCT02617589], press release). Nivolumab is currently
also being explored in the CheckMate 548 trial
(NCT02667587), in patients with newly diagnosed
glioblastoma with MGMT promoter methylation. The an-
tibody-drug conjugate depatuxizumab-mafodotin was as-
sessed in patients with recurrent EGFR-amplified glioblas-
toma. Although the primary endpoint of the trial was not
met, a long-term analysis suggested that the drug may be
active [51]. Yet, according to a press release, the addi-
tion of depatuxizumab-mafodotin to the standard of care
in patients with newly diagnosed glioblastoma harboring
an EGFR amplification did not prolong overall survival
(NCT02573324). Marizomib, a brain-penetrant pan-pro-
teasome inhibitor is currently examined in patients with
newly diagnosed glioblastoma in a randomised phase III
trial (EORTC 1709, NCT03345095). Furthermore, molec-
ular alterations such as BRAFV600E mutations, which are
found in a subset of gliomas, will be used more frequently
for targeted therapeutic strategies in the future [52, 53].
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